Skip to main content
TipRanks
Go Ultimate75% OFF

Kyverna Therapeutics, Inc. (KYTX) Stock Statistics & Valuation Metrics

1,057 Followers

Total Valuation

Kyverna Therapeutics, Inc. has a market cap or net worth of $319.27M. The enterprise value is $283.21M.

Market Cap
$319.27M
Enterprise Value
$283.21M

Share Statistics

Kyverna Therapeutics, Inc. has 63,221,970 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
63,221,970
Owned by Insiders
22.84%
Owned by Institutions
37.58%

Financial Efficiency

Kyverna Therapeutics, Inc.’s return on equity (ROE) is -0.69 and return on invested capital (ROIC) is -64.99%.

Return on Equity (ROE)
-0.69
Return on Assets (ROA)
-0.55
Return on Invested Capital (ROIC)
-64.99%
Return on Capital Employed (ROCE)
-0.66
Revenue Per Employee
0
Profits Per Employee
-1.08M
Employee Count
149
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Kyverna Therapeutics, Inc. is -1.82. Kyverna Therapeutics, Inc.’s PEG ratio is -0.06.

PE Ratio
-1.82
PS Ratio
0.00
PB Ratio
2.35
Price to FCF
-2.11
Price to Operating Cash Flow
-2.07
PEG Ratio
-0.06

Income Statement

In the last 12 months, Kyverna Therapeutics, Inc. had revenue of 0 and earned -161.31M in profits. Earnings per share was -3.64.

Revenue
0
Gross Profit
0
Operating Income
-169.83M
Pretax Income
-161.31M
Net Income
-161.31M
EBITDA
-159.02M
Earnings Per Share (EPS)
-3.64

Cash Flow

In the last 12 months, operating cash flow was -150.80M and capital expenditures -462,000, giving a free cash flow of -151.26M billion.

Operating Cash Flow
-150.80M
Free Cash Flow
-151.26M
Free Cash Flow per Share
-2.44

Dividends & Yields

Kyverna Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-47.38%
Earnings Yield
-50.43%

Stock Price Statistics

Beta
1.90
52-Week Price Change
-22.07%
50-Day Moving Average
6.28
200-Day Moving Average
7.91
Relative Strength Index (RSI)
39.06
Average Volume (3m)
864.35K

Important Dates

Kyverna Therapeutics, Inc. upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 12, 2026
Next Earnings Date
Apr 01, 2027
Ex-Dividend Date
―

Financial Position

Kyverna Therapeutics, Inc. as a current ratio of 7.75, with Debt / Equity ratio of 12.50%

Current Ratio
7.75
Quick Ratio
7.75
Debt to Market Cap
0.06
Net Debt to EBITDA
0.60
Interest Coverage Ratio
-347.29

Taxes

In the past 12 months, Kyverna Therapeutics, Inc. has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Kyverna Therapeutics, Inc. EV to EBITDA ratio is -2.08, with an EV/FCF ratio of -2.11.

EV to Sales
0.00
EV to EBITDA
-2.08
EV to Free Cash Flow
-2.11
EV to Operating Cash Flow
-2.12

Balance Sheet

Kyverna Therapeutics, Inc. has $170.57M in cash and marketable securities with $32.45M in debt, giving a net cash position of $138.12M billion.

Cash & Marketable Securities
$170.57M
Total Debt
$32.45M
Net Cash
$138.12M
Net Cash Per Share
$2.18
Tangible Book Value Per Share
$2.15

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Kyverna Therapeutics, Inc. is $29.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$29.00
Price Target Upside
474.26% Upside
Analyst Consensus
Strong Buy
Analyst Count
3
Revenue Growth Forecast
―
EPS Growth Forecast
25.69%

Scores

Smart Score
5
AI Score
47